Page last updated: 2024-08-17

levodopa and opicapone

levodopa has been researched along with opicapone in 50 studies

Research

Studies (50)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	25 (50.00)	24.3611
2020's	25 (50.00)	2.80

Authors

Authors	Studies
Bonifácio, MJ; Ferreira, HS; Kiss, LE; Learmonth, DA; Palma, PN; Soares-da-Silva, P; Torrão, L	1
Bonifácio, MJ; Soares-da-Silva, P; Sutcliffe, JS; Torrão, L; Wright, LC	1
Falcão, A; Lopes, N; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P; Vaz-da-Silva, M; Wright, LC	1
Kiss, LE; Soares-da-Silva, P	1
Bonifácio, MJ; Loureiro, AI; Palma, PN; Soares-da-Silva, P; Torrão, L; Wright, LC	1
Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P	1
Ferreira, JJ; Lees, A; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P	2
Devos, D; Moreau, C	1
Almeida, L; Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P	1
Scott, LJ	1
Fabbri, M; Ferreira, JJ; Rosa, MM	1
Almeida, L; Bonifácio, MJ; Falcão, A; Fauchoux, N; Loureiro, AI; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Sicard, É; Soares-da-Silva, P	1
Ferreira, J; Lees, AJ; McCrory, M; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P	1
Annus, Á; Vécsei, L	1
Huang, X; Zhang, Y	1
Lees, AJ; Rocha, JF; Soares-da-Silva, P	1
Ferreira, J; Lees, AJ; Poewe, W; Rascol, O; Reichmann, H; Stocchi, F; Tolosa, E	1
Kostić, V; Kresojević, N; Svetel, M; Tomić, A	1
Antonini, A; Godeiro, C; Moro, E; Reichmann, H	1
Ferreira, JJ; Keller, B; Lees, AJ; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P	1
Fabbri, M; Ferreira, JJ; Lees, A; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E	1
Januário, C; Moreira, F; Rebelo Gomes, I	1
Ferreira, JJ; Gama, H; Lees, A; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P	1
Klivényi, P; Salamon, A; Szpisjak, L; Vécsei, L; Zádori, D	1
Auladell, C; Busquets, O; Camins, A; Cano, A; Ettcheto, M; Folch, J; Manzine, PR; Olloquequi, J; Sánchez-Lopez, E; Verdaguer, E	1
García Ruiz-Espiga, P; Linazasoro-Cristóbal, G; López Del Val, LJ; López-Manzanares, L; Luquin-Piudo, MR; Martínez-Castrillo, JC; Mir, P; Pagonabarraga-Mora, J	1
Chaudhuri, KR; Jones, S; Leta, V; Parry, M; Rizos, A; Sauerbier, A; van Wamelen, DJ	1
Müller, T	1
Hattori, N; Maeda, T; Nishimura, A; Nomoto, M; Takahashi, R; Takeda, A; Tsuboi, Y; Yoshida, K	2
Bonifácio, MJ; Soares-da-Silva, P; Sousa, F	1
Cavallieri, F; Fioravanti, V; Valzania, F	1
Fabbri, M; Leung, C; Rascol, O	1
Da Silva, JD; Meira-Carvalho, F; Rodrigues, M	1
Feldman, M; Margolesky, J	1
Ishii, K; Nakamagoe, K; Tamaoka, A; Tsuji, H	1
Ferreira, JJ; Jenner, P; Rascol, O; Rocha, JF; Soares-da-Silva, P	1
Larson, D; Simuni, T	1
Abril-Jaramillo, J; Almeida, F; Bermejo, P; Borrue, C; Caballol, N; Campins-Romeu, M; Clavero, P; García-Caldentey, J; Gómez-Mayordomo, V; Labandeira, C; López-Ariztegui, N; Martí-Andrés, G; Martínez-Castrillo, JC; Martinez-Poles, J; Mata-Alvarez Santullano, M; Muñoz, T; Rico-Villademoros, F; Rojo, R; Salom, JM; Sarasa, P; Tegel, I; Valderrama-Martín, C; Vinagre-Aragón, A	1
Kang, HY; Kwak, N; Lee, H; Lee, MJ; Park, J; Suh, JK	1
Carroll, C; Chaudhuri, KR; Evans, J; Foltynie, T; Lees, A; Pavese, N; Reichmann, H; Schofield, C; Sharma, JC; Soares-da-Silva, P; Zurowska, L	1
Eggert, K; Kemmer, M; Lees, AJ; Oehlwein, C; Reichmann, H; Soares-da-Silva, P; Warnecke, T	1
Müller, T; Schlegel, E; Thiede, HM; Zingler, S	1
Brzostek, T; Kawalec, P; Śladowska, K; Żegleń, M	1
Antonini, A; Ferreira, JJ; Guimarães, B; Moreira, J; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P; Stocchi, F	1
Ando, R; Ito, YH; Miyaue, N; Nagai, M; Ochi, C; Tada, S; Yamanishi, Y	1
Aureli, F; Cortelli, P; Leta, V; Metta, V; Ray Chaudhuri, K; Rizos, A; Rodriguez-Blazquez, C; Trivedi, D; van Wamelen, DJ	1
Castilla-Fernández, G; Chaudhuri, KR; Di Foggia, V; Harrison-Jones, G; Marston, XL; Morgante, F	1
Antonini, A; Barone, P; Calabresi, P; Lopiano, L; Morgante, F; Pontieri, FE; Sensi, M; Stocchi, F	1

Reviews

17 review(s) available for levodopa and opicapone

Article	Year
Opicapone: A Review in Parkinson's Disease. Drugs, 2016, Volume: 76, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Oxadiazoles; Parkinson Disease	2016
Clinical pharmacology review of opicapone for the treatment of Parkinson's disease. Neurodegenerative disease management, 2016, Volume: 6, Issue:5 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Pharmacology, Clinical	2016
Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy. Drug design, development and therapy, 2017, Volume: 11 Topics: Antiparkinson Agents; Drug Design; Drug Therapy, Combination; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2017
Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. Expert review of neurotherapeutics, 2017, Volume: 17, Issue:7 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2017
Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease. Expert opinion on drug metabolism & toxicology, 2018, Volume: 14, Issue:3 Topics: Adult; Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Food-Drug Interactions; Half-Life; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2018
Medical and surgical management of advanced Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:6 Topics: Animals; Antiparkinson Agents; Deep Brain Stimulation; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2018
Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:10 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2018
Opicapone for the treatment of Parkinson's disease: an update. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:18 Topics: Administration, Oral; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease	2019
The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. Expert opinion on drug discovery, 2020, Volume: 15, Issue:9 Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Drug Development; Drug Evaluation, Preclinical; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2020
Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts. Revista de neurologia, 2020, Jun-12, Volume: 70, Issue:s01 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Dopamine Agonists; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease; Patient Selection; Treatment Outcome	2020
Safinamide in the treatment of Parkinson's disease. Neurodegenerative disease management, 2020, Volume: 10, Issue:4 Topics: Adolescent; Adult; Alanine; Antiparkinson Agents; Benzylamines; Catechol O-Methyltransferase Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Young Adult	2020
Opicapone for the treatment of Parkinson's disease: a review. The International journal of neuroscience, 2023, Volume: 133, Issue:5 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Clinical Trials, Phase IV as Topic; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2023
Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. Expert review of neurotherapeutics, 2021, Volume: 21, Issue:9 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2021
New dopaminergic therapies for PD motor complications. Neuropharmacology, 2022, 02-15, Volume: 204 Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2022
[Opicapone for the treatment of Parkinson's disease: real-life data in Spain]. Revista de neurologia, 2021, 12-24, Volume: 73, Issue:s02 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Combined Modality Therapy; Deep Brain Stimulation; Drug Therapy, Combination; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Spain; Treatment Outcome	2021
Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's disease, 2022, Volume: 12, Issue:3 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Randomized Controlled Trials as Topic	2022
Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis. Journal of comparative effectiveness research, 2022, Volume: 11, Issue:12 Topics: Adult; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2022

Trials

11 trial(s) available for levodopa and opicapone

Article	Year
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. European journal of clinical pharmacology, 2014, Volume: 70, Issue:9 Topics: Adult; Antiparkinson Agents; Area Under Curve; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Oxadiazoles; Young Adult	2014
Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. European journal of neurology, 2015, Volume: 22, Issue:5 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome	2015
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. The Lancet. Neurology, 2016, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Europe; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Oxadiazoles; Parkinson Disease	2016
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. Clinical pharmacology in drug development, 2016, Volume: 5, Issue:3 Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease	2016
Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics. British journal of clinical pharmacology, 2017, Volume: 83, Issue:3 Topics: Adult; Antiparkinson Agents; Benserazide; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles	2017
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA neurology, 2017, Feb-01, Volume: 74, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; International Cooperation; Levodopa; Male; Middle Aged; Motor Activity; Oxadiazoles; Parkinson Disease; Severity of Illness Index	2017
Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. European journal of neurology, 2019, Volume: 26, Issue:7 Topics: Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome	2019
Safety Profile of Opicapone in the Management of Parkinson's Disease. Journal of Parkinson's disease, 2019, Volume: 9, Issue:4 Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome	2019
Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations. Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Humans; Japan; Levodopa; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome; United Kingdom	2021
Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations. Journal of neural transmission (Vienna, Austria : 1996), 2021, Volume: 128, Issue:3 Topics: Antiparkinson Agents; Double-Blind Method; Humans; Japan; Levodopa; Oxadiazoles; Parkinson Disease	2021
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society, 2022, Volume: 37, Issue:11 Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Humans; Levodopa; Parkinson Disease	2022

Other Studies

22 other study(ies) available for levodopa and opicapone

Article	Year
Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. Journal of medicinal chemistry, 2010, Apr-22, Volume: 53, Issue:8 Topics: Animals; Antiparkinson Agents; Brain; Catechol O-Methyltransferase Inhibitors; Drug Interactions; In Vitro Techniques; Levodopa; Liver; Oxadiazoles; Rats; Rats, Wistar; Structure-Activity Relationship	2010
Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Neuropharmacology, 2014, Volume: 77 Topics: Animals; Antiparkinson Agents; Brain; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dopamine Agents; Drug Interactions; Female; Levodopa; Macaca fascicularis; Male; Oxadiazoles; Parkinson Disease	2014
Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility. Journal of medicinal chemistry, 2014, Nov-13, Volume: 57, Issue:21 Topics: Acetophenones; Animals; Catalysis; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Crystallography, X-Ray; Humans; Inhibitory Concentration 50; Levodopa; Male; Models, Molecular; Nitriles; Oxadiazoles; Parkinson Disease; Prodrugs; Rats	2014
Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. British journal of pharmacology, 2015, Volume: 172, Issue:7 Topics: Adenosine Triphosphate; Animals; Antiparkinson Agents; Benzophenones; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cell Survival; Cells, Cultured; Hepatocytes; Humans; Levodopa; Male; Membrane Potential, Mitochondrial; Models, Biological; Nitriles; Nitrophenols; Oxadiazoles; Rats, Wistar; Tolcapone	2015
Opicapone for motor fluctuations in Parkinson's disease. The Lancet. Neurology, 2016, Volume: 15, Issue:2 Topics: Antiparkinson Agents; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2016
Concerns Regarding Opicapone as Adjunct to Levodopa Therapy. JAMA neurology, 2017, 07-01, Volume: 74, Issue:7 Topics: Antiparkinson Agents; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2017
Concerns Regarding Opicapone as Adjunct to Levodopa Therapy-Reply. JAMA neurology, 2017, 07-01, Volume: 74, Issue:7 Topics: Antiparkinson Agents; Humans; Levodopa; Oxadiazoles	2017
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology, 2018, 05-22, Volume: 90, Issue:21 Topics: Aged; Antiparkinson Agents; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Oxadiazoles; Parkinson Disease; Treatment Outcome	2018
Freezing of gait and postural instability: the unpredictable response to levodopa in Parkinson's disease. BMJ case reports, 2019, Jul-22, Volume: 12, Issue:7 Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Gait Disorders, Neurologic; Humans; Levodopa; Male; Oxadiazoles; Parkinson Disease; Postural Balance; Sensation Disorders	2019
Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems? Journal of Parkinson's disease, 2020, Volume: 10, Issue:4 Topics: Aged; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cost Savings; Delivery of Health Care; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Retrospective Studies	2020
Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys. European journal of pharmacology, 2021, Feb-05, Volume: 892 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catechol O-Methyltransferase Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Erythrocytes; Female; Levodopa; Locomotion; Macaca fascicularis; Oxadiazoles; Parkinsonian Disorders; Time Factors	2021
Opicapone and acute levodopa challenge test: the big issue. Acta neurologica Belgica, 2021, Volume: 121, Issue:5 Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Oxadiazoles; Parkinson Disease; Treatment Outcome	2021
Opicapone for Parkinson's disease: clinical evidence and future perspectives. Neurodegenerative disease management, 2021, Volume: 11, Issue:3 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2021
Opicapone in Parkinson's Disease: Real-World Data from a Portuguese Center. European neurology, 2021, Volume: 84, Issue:2 Topics: Antiparkinson Agents; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Portugal	2021
Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:11 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease	2021
Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease. Neurodegenerative disease management, 2022, Volume: 12, Issue:2 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Costs and Cost Analysis; Double-Blind Method; Humans; Levodopa; Oxadiazoles; Parkinson Disease; United Kingdom	2022
Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations. European neurology, 2022, Volume: 85, Issue:5 Topics: Activities of Daily Living; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Germany; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2022
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients. Cells, 2022, 04-30, Volume: 11, Issue:9 Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Homocysteine; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease	2022
Impact of concomitant use of opicapone during levodopa-carbidopa intestinal gel treatment. Journal of the neurological sciences, 2023, 02-15, Volume: 445 Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Oxadiazoles	2023
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone. Journal of neural transmission (Vienna, Austria : 1996), 2023, Volume: 130, Issue:7 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease; Retrospective Studies	2023
Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment. European journal of neurology, 2023, Volume: 30, Issue:10 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Patient Acceptance of Health Care; Retrospective Studies	2023
The role of opicapone in the management of Parkinson's disease: an Italian consensus through a combined Nominal Group Technique and Delphi approach. European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:18 Topics: Catechol O-Methyltransferase; Consensus; Humans; Levodopa; Parkinson Disease	2023